{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:44:45Z","timestamp":1792449885134,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009473","name":"Universidad de M\u00e1laga","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is strongly linked to obesity, type 2 diabetes, and cardiovascular disease. Growing evidence highlights the role of the gut\u2013liver axis, particularly microbial metabolites such as the short-chain fatty acid (SCFA) butyrate, in MASLD pathophysiology. However, clinical data on butyrate levels and the abundance of butyrate-producing bacteria in MASLD patients remain inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically synthesize human evidence evaluating the associations between butyrate levels and butyrate-producing gut bacteria with MASLD presence and severity, as well as related metabolic comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed and Embase from inception to April 7, 2025, following PRISMA 2020 guidelines (PROSPERO registration CRD420251162439). Eligible studies included observational human research assessing fecal or plasma SCFA concentrations and\/or the abundance of butyrate-producing taxa in adults with MASLD and related metabolic disorders. Study quality was appraised using the Newcastle\u2013Ottawa Scale, and results were narratively synthesized due to heterogeneity across methods and outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 233 records, seven studies met inclusion criteria (2020\u20132025;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,185). Most were cross-sectional or case\u2013control designs of moderate to high quality (NOS 6\u20138\/9). Individuals with MASLD generally exhibited lower fecal or serum butyrate concentrations and reduced abundance of\n                      <jats:italic>Faecalibacterium prausnitzii<\/jats:italic>\n                      ,\n                      <jats:italic>Eubacterium<\/jats:italic>\n                      , and other butyrate-producing bacteria versus controls. These alterations were associated with hepatic steatosis, fibrosis, inflammation, and adverse metabolic profiles - higher BMI, insulin resistance, and dyslipidemia. Geographic and sex-related differences were also reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This systematic review suggests that reduced butyrate availability and alterations in butyrate-producing gut taxa are associated with MASLD presence and severity and with adverse metabolic traits. However, substantial methodological heterogeneity and the observational design of available studies preclude causal inference. Larger, well-phenotyped, multicentre studies using standardized SCFA quantification, dietary and medication ascertainment, and functional microbiome profiling are needed to validate these findings and clarify their diagnostic and therapeutic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00694-8","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:16:02Z","timestamp":1772601362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8020-2531","authenticated-orcid":false,"given":"Alicia","family":"Gonz\u00e1lez-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3285-7194","authenticated-orcid":false,"given":"Virginia","family":"Soria-Utrilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4868-0127","authenticated-orcid":false,"given":"Mar\u00eda Isabel","family":"Fontalba-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"N\u00fa\u00f1ez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1539-057X","authenticated-orcid":false,"given":"Antonio","family":"Adarve-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel","family":"Queipo-Ortu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ramos-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9761-6888","authenticated-orcid":false,"given":"Jos\u00e9 Ignacio","family":"Mart\u00ednez-Montoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Carlos","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"issue":"7","key":"694_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic Dysfunction-Associated Steatotic Liver Disease. N Engl J Med. 2025;393(7):683\u201398.","journal-title":"N Engl J Med"},{"issue":"4","key":"694_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatol. 2023;77(4):1335\u201347.","journal-title":"Hepatol"},{"issue":"Suppl","key":"694_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"694_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"issue":"7","key":"694_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterol. 2020;158(7):1851\u201364.","journal-title":"Gastroenterol"},{"issue":"3","key":"694_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5114\/ceh.2023.130744","volume":"9","author":"AE Platek","year":"2023","unstructured":"Platek AE, Szymanska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Exp Hepatol. 2023;9(3):187\u201392.","journal-title":"Clin Exp Hepatol"},{"issue":"3","key":"694_CR7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"key":"694_CR8","doi-asserted-by":"publisher","first-page":"502442","DOI":"10.1016\/j.gastrohep.2025.502442","volume":"502442","author":"M Romero-G\u00f3mez","year":"2025","unstructured":"Romero-G\u00f3mez M, Escalada J, Noguerol M, P\u00e9rez A, Carretero J, Crespo J et al. Gu\u00eda de pr\u00e1ctica cl\u00ednica multidisciplinar de manejo de la esteatosis hep\u00e1tica metab\u00f3lica. Gastroenterolog\u00eda y hepatolog\u00eda. 2025;502442.","journal-title":"Gastroenterolog\u00eda y hepatolog\u00eda"},{"key":"694_CR9","unstructured":"Research C, for DE. and. FDA Approves Treatment for Serious Liver Disease Known as \u2018MASH\u2019. FDA. 2025. Available at https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash."},{"issue":"1","key":"694_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/livers5010011","volume":"5","author":"F Abdelhameed","year":"2025","unstructured":"Abdelhameed F, Mustafa A, Kite C, Lagojda L, Dallaway A, Than NN, et al. Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications. Livers. 2025;5(1):11.","journal-title":"Livers"},{"issue":"3","key":"694_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558\u201377.","journal-title":"J Hepatol"},{"issue":"9","key":"694_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","volume":"22","author":"HCH Lau","year":"2025","unstructured":"Lau HCH, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;22(9):619\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"694_CR13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1055\/a-2438-4383","volume":"44","author":"S Maher","year":"2024","unstructured":"Maher S, Rajapakse J, El-Omar E, Zekry A. Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease. Semin Liver Dis. 2024;44(4):457\u201373.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"694_CR14","doi-asserted-by":"publisher","first-page":"2500099","DOI":"10.1080\/19490976.2025.2500099","volume":"17","author":"H Wu","year":"2025","unstructured":"Wu H, Chen J, Guo S, Deng J, Zhou Z, Zhang X, et al. Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease. Gut Microbes. 2025;17(1):2500099.","journal-title":"Gut Microbes"},{"issue":"13","key":"694_CR15","doi-asserted-by":"publisher","first-page":"fnz153","DOI":"10.1093\/femsle\/fnz153","volume":"366","author":"S Zhai","year":"2019","unstructured":"Zhai S, Qin S, Li L, Zhu L, Zou Z, Wang L. Dietary butyrate suppresses inflammation through modulating gut microbiota in high-fat diet-fed mice. FEMS Microbiol Lett. 2019;366(13):fnz153.","journal-title":"FEMS Microbiol Lett"},{"issue":"15","key":"694_CR16","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.3390\/ijms21155214","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020;21(15):5214.","journal-title":"Int J Mol Sci"},{"issue":"15","key":"694_CR17","doi-asserted-by":"publisher","first-page":"e42101","DOI":"10.1097\/MD.0000000000042101","volume":"104","author":"H Xu","year":"2025","unstructured":"Xu H, Wang X, Song S, Zhang L. Efficacy of sodium butyrate in improving nonalcoholic fatty liver disease: A meta-analysis of preclinical studies. Med (Baltim). 2025;104(15):e42101.","journal-title":"Med (Baltim)"},{"issue":"15","key":"694_CR18","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.3390\/nu16152454","volume":"16","author":"F Di Fogacci","year":"2024","unstructured":"Fogacci F, Giovannini M, Di Micoli V, Grandi E, Borghi C, Cicero AFG. Effect of Supplementation of a Butyrate-Based Formula in Individuals with Liver Steatosis and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial. Nutrients. 2024;16(15):2454.","journal-title":"Nutrients"},{"issue":"9","key":"694_CR19","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s10620-016-4179-1","volume":"61","author":"Z Pataky","year":"2016","unstructured":"Pataky Z, Genton L, Spahr L, Lazarevic V, Terraz S, Ga\u00efa N, et al. Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci. 2016;61(9):2721\u201331.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"694_CR20","doi-asserted-by":"publisher","first-page":"732","DOI":"10.36740\/WLek202404118","volume":"77","author":"OK Didyk","year":"2024","unstructured":"Didyk OK, Chernyavskyi VV, Shypulin VP, Tishchenko VV. Effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus. Wiad Lek. 2024;77(4):732\u20138.","journal-title":"Wiad Lek"},{"issue":"1","key":"694_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"key":"694_CR22","doi-asserted-by":"publisher","first-page":"1113643","DOI":"10.3389\/fcimb.2023.1113643","volume":"13","author":"LT Jin","year":"2023","unstructured":"Jin LT, Xu MZ. Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease. Front Cell Infect Microbiol. 2023;13:1113643.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"694_CR23","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3390\/nu15071712","volume":"15","author":"HJ Tsai","year":"2023","unstructured":"Tsai HJ, Hung WC, Hung WW, Lee YJ, Chen YC, Lee CY, et al. Circulating Short-Chain Fatty Acids and Non-Alcoholic Fatty Liver Disease Severity in Patients with Type 2 Diabetes Mellitus. Nutrients. 2023;15(7):1712.","journal-title":"Nutrients"},{"issue":"8","key":"694_CR24","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1111\/jgh.15487","volume":"36","author":"M Iwaki","year":"2021","unstructured":"Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36(8):2275\u201384.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"694_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41366-019-0430-0","volume":"44","author":"G Aragon\u00e8s","year":"2020","unstructured":"Aragon\u00e8s G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Mart\u00ednez S, Sabench F, et al. Circulating microbiota-derived metabolites: a liquid biopsy? Int J Obes (Lond). 2020;44(4):875\u201385.","journal-title":"Int J Obes (Lond)"},{"issue":"8","key":"694_CR26","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.3390\/ijms25084387","volume":"25","author":"A Zazueta","year":"2024","unstructured":"Zazueta A, Valenzuela-P\u00e9rez L, Ortiz-L\u00f3pez N, Pinto-Le\u00f3n A, Torres V, Gui\u00f1ez D, et al. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Int J Mol Sci. 2024;25(8):4387.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"694_CR27","doi-asserted-by":"publisher","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","volume":"16","author":"R Forlano","year":"2024","unstructured":"Forlano R, Martinez-Gili L, Takis P, Miguens-Blanco J, Liu T, Triantafyllou E, et al. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus. Gut Microbes. 2024;16(1):2304157.","journal-title":"Gut Microbes"},{"issue":"1","key":"694_CR28","doi-asserted-by":"publisher","first-page":"2482158","DOI":"10.1080\/21505594.2025.2482158","volume":"16","author":"D Zhang","year":"2025","unstructured":"Zhang D, Wang Q, Li D, Chen S, Chen J, Zhu X, et al. Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease. Virulence. 2025;16(1):2482158.","journal-title":"Virulence"},{"key":"694_CR29","doi-asserted-by":"publisher","first-page":"1490929","DOI":"10.3389\/fmed.2024.1490929","volume":"11","author":"LJ Wang","year":"2025","unstructured":"Wang LJ, Sun JG, Chen SC, Sun YL, Zheng Y, Feng JC. The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies. Front Med (Lausanne). 2025;11:1490929.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"694_CR30","doi-asserted-by":"publisher","first-page":"103854","DOI":"10.4254\/wjh.v17.i3.103854","volume":"17","author":"JZ Shu","year":"2025","unstructured":"Shu JZ, Huang YH, He XH, Liu FY, Liang QQ, Yong XT, et al. Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression. World J Hepatol. 2025;17(3):103854.","journal-title":"World J Hepatol"},{"issue":"9","key":"694_CR31","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","volume":"54","author":"G den Besten","year":"2013","unstructured":"den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013;54(9):2325\u201340.","journal-title":"J Lipid Res"},{"issue":"7","key":"694_CR32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/db08-1637","volume":"58","author":"Z Gao","year":"2009","unstructured":"Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M, et al. Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice. Diabetes2009;58(7):1509\u201317.","journal-title":"Diabetes"},{"key":"694_CR33","doi-asserted-by":"publisher","first-page":"103293","DOI":"10.1016\/j.ebiom.2021.103293","volume":"66","author":"S Deleu","year":"2021","unstructured":"Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? eBioMedicine. 2021;66:103293.","journal-title":"eBioMedicine"},{"issue":"1","key":"694_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/nu17010053","volume":"17","author":"R Salvado","year":"2024","unstructured":"Salvado R, Lugones-S\u00e1nchez C, Santos-Minguez S, Gonz\u00e1lez-S\u00e1nchez S, Quesada JA, Benito R, et al. Sex Differences in Gut Microbiota and Their Relation to Arterial Stiffness (MIVAS Study). Nutrients. 2024;17(1):53.","journal-title":"Nutrients"},{"issue":"4","key":"694_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3390\/biomedicines13040855","volume":"13","author":"I Milani","year":"2025","unstructured":"Milani I, Chinucci M, Leonetti F, Capoccia D. MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines. 2025;13(4):855.","journal-title":"Biomedicines"},{"issue":"1","key":"694_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12964-023-01219-9","volume":"21","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jian YP, Zhang YN, Li Y, Gu LT, Sun HH, et al. Short-chain fatty acids in diseases. Cell Commun Signal. 2023;21(1):212.","journal-title":"Cell Commun Signal"},{"issue":"16","key":"694_CR37","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1016\/j.cell.2021.06.019","volume":"184","author":"HC Wastyk","year":"2021","unstructured":"Wastyk HC, Fragiadakis GK, Perelman D, Dahan D, Merrill BD, Yu FB, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137\u2013e415314.","journal-title":"Cell"},{"issue":"11","key":"694_CR38","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3390\/nu17111753","volume":"17","author":"W Krauze","year":"2025","unstructured":"Krauze W, Busz N, Piku\u0142a W, Maternowska M, Prowans P, Maciejewska-Markiewicz D. Effect of Sodium Butyrate Supplementation on Type 2 Diabetes-Literature Review. Nutrients. 2025;17(11):1753.","journal-title":"Nutrients"},{"issue":"2","key":"694_CR39","doi-asserted-by":"publisher","first-page":"e13367","DOI":"10.1111\/obr.13367","volume":"23","author":"JI Mart\u00ednez-Montoro","year":"2022","unstructured":"Mart\u00ednez-Montoro JI, Kuchay MS, Balaguer-Rom\u00e1n A, Mart\u00ednez-S\u00e1nchez MA, Frutos MD, Fern\u00e1ndez-Garc\u00eda JC, et al. Gut microbiota and related metabolites in the pathogenesis of nonalcoholic steatohepatitis and its resolution after bariatric surgery. Obes Rev. 2022;23(2):e13367.","journal-title":"Obes Rev"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00694-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00694-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:17:44Z","timestamp":1781637464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00694-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00694-8","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}